First-in-class SCS Microinjection therapy
First clinical registration study and potentially the first approved drug in China targeting macular edema associated with uveitis
U.S. FDA approved for treatment of macular edema associated with uveitisSHANGHAI, Nov. 22, 2021 /PRNewswire/ -- Arctic Vision, a China-based biotech company focused on innovative ophthalmic therapies, announced on Nov. 19 that the first set of patients have been dosed in the Phase III study of ARVN001 (triamcinolone acetonide suprachoroidal injectable suspension, known as XIPERE
